Table 1. Peptides examined in this study... | American Society of Hematology

Table 1.

Peptides examined in this study

Protein^*	Sequence	C₅₀, μM†
HIV-1 pol₄₇₆	ILKEPVHGV	0.7
Bcl₂₂₄	A L V G A C I T L	0.7
Bcl₈₅	A L S P V P P V V	1
bcl₂₂₂	S L A L V G A C I	1
bcl₂₁₈	K T L L S L A L V	2
bcl₂₂₀	L L S L A L V G A	1
bcl₂₁₄	W L S L K T L L S L	> 100
bcl₈₀	A A A G P A L S P V	36
bcl₂₁₆	S L K T L L S L A L	Not binding
bcl₂₀₈	P L F D F S W L S L	7
bcl₁₂₄	F T A R G R F A T V	1
bcl₁₈₀	Y L N R H L H T W I	10
bcl₁₇₂	N I A L W M T E Y L	> 100
bcl₂₀₀	E L Y G P S M R P L	Not binding

Protein^*	Sequence	C₅₀, μM†
HIV-1 pol₄₇₆	ILKEPVHGV	0.7
Bcl₂₂₄	A L V G A C I T L	0.7
Bcl₈₅	A L S P V P P V V	1
bcl₂₂₂	S L A L V G A C I	1
bcl₂₁₈	K T L L S L A L V	2
bcl₂₂₀	L L S L A L V G A	1
bcl₂₁₄	W L S L K T L L S L	> 100
bcl₈₀	A A A G P A L S P V	36
bcl₂₁₆	S L K T L L S L A L	Not binding
bcl₂₀₈	P L F D F S W L S L	7
bcl₁₂₄	F T A R G R F A T V	1
bcl₁₈₀	Y L N R H L H T W I	10
bcl₁₇₂	N I A L W M T E Y L	> 100
bcl₂₀₀	E L Y G P S M R P L	Not binding

The value range listed in subscript indicates the position of the first amino acid in the sequence

The C₅₀ value is the concentration of the peptide required for half-maximal binding to HLA-A2